Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents

Primary series vaccination with BNT162b2 followed by a booster 5 months later has been recommended for healthy adolescents. We aimed to describe the immunogenicity in a fractional dose of BNT162b2. Adolescents aged 12–18 years were randomized into six arms for primary series administration: 3wPZ30/3...

Full description

Bibliographic Details
Main Authors: Thanyawee Puthanakit, Napaporn Chantasrisawad, Kirana Yoohat, Rapisa Nantanee, Jiratchaya Sophonphan, Thutsanun Meepuksom, Pimpayao Sodsai, Supranee Phanthanawiboon, Watsamon Jantarabenjakul, Nattiya Hirankarn, Pope Kosalaraksa
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Vaccines
Subjects:
SARS-CoV-2 vaccine
adolescents
neutralizing antibody titer
anti-SARS-CoV-2
fractional dose
BNT162b2
Online Access:https://www.mdpi.com/2076-393X/10/10/1646

Internet

https://www.mdpi.com/2076-393X/10/10/1646

Similar Items